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Support of biomedical research is one of the rare
themes that unify members of Congress and administra-
tion officials, the two political parties, and the public.
Although the private research sector has grown larger
and more powerful than the public sector, the symbol
of this support continues to be the National Institutes of
Health (NIH), the most visible public research en-
deavor. During the last two decades, as both domestic
and defense spending generated hot debates, the NIH
budget got unprecedented backing. Urged by disease
lobbies, eminent scientists, movie stars, former first
ladies, famous athletes, and even news people, Con-
gress and the Clinton administration moved the NIH
budget from less than $11 billion in 1993, when Harold
Varmus, M.D., became the NIH director, to $15.6
billion in 1999. Over the same period of time, research-
based pharmaceutical firms' investment in research and
development (R&D) went from approximately $12
billion to an estimated $24 billion. Congress and the
administration agreed to $17.9 billion for 2000, with
the stipulation that the NIH delay spending $7.5 billion
of the amount until the end of the federal fiscal year.
The impact of biomedical research on Medicare and
Medicaid expenditures, as well as other public and
private health care outlays, is significant as well. “The
United States leads the world both in demand for health
care advances and in the research and development
(R&D) that produce these advances,” Burton A.
Weibrod and Craig L. LaMay asserted in a recent
Health Affairs article. “The primary reason for the
increase in the health sector's share of the Gross Do-
mestic Product over the past 30 years is technological
change in medicine.”
The biomedical research enterprise is traditionally an
amalgam of public and private partners and competitors.
On the public side, in addition to the NIH, the enterprise
includes agencies focused on access, cost, and quality;
disease prevention and health promotion; drugs, food,
cosmetics, medical and diagnostic devices, and other
products; and services provided under the Medicare,
Medicaid, and Child Health Insurance Programs (CHIP),
as well as under the Department of Veterans Affairs
(VA). On the private side, the enterprise encompasses
pharmaceutical firms, biotechnology companies, and
medical equipment manufacturers that, regardless of their
proprietary status, take guidance from regulators. More-
over, public and private academic health centers (AHCs),
managed care organizations (MCOs), and other providers
serve as loci for funded projects, while practiced-based
research networks (PBRNs) and contract research
organizations (CROs) act as conduits for funds for a
range of activities. Sometimes more compartmentalized
than continuous, these activities include basic, transla-
tional, clinical, and outcomes research.
But even as the U.S. biomedical research enterprise
is heralded for the drugs and procedures it has developed
to fight a bevy of diseases and conditions, it is the
subject of dire warnings, particularly in clinical research.
Throughout the 1990s, scientists sounded alarms of
crisis in the proportion of effort and funding devoted to
patient- and population-oriented research and in the
number of investigators available to conduct such
research. Various groups convened under separate
auspices to address the crisis and to develop recommen-
dations to help resolve it. Hosts included the NIH, the
Institute of Medicine (IOM), and the Commonwealth
Fund; the Association of American Medical Colleges
(AAMC), the American Medical Association (AMA),
and the Wake Forest University School of Medicine
collaborated to convene focus groups and a consensus-
seeking conference.
While there is near unanimity on the importance of
biomedical research in this country, there is considerable
dissension over the priorities that drive various aspects
of the field. There is also contention over implementa-
tion of research priorities in the public and private
sectors and the interface between the two. Moreover,
there is considerable disagreement over the leadership of
biomedical research. This has come about as the private
sector has surpassed the public sector in the extent and
financing of projects and as the traditional tripartite
mission of AHCs—service delivery, medical education,
and research—has come under challenge in the rapidly
changing health marketplace. Likely to add fuel to the
debate is the recent announcement by Varmus—the de
facto leader of the biomedical research arena—that he
will leave his post as NIH director at the end of this year
to head the private Memorial Sloan-Kettering Cancer
Center. Rep. John Porter (R-Ill.), chairman of the House
Appropriations Committee subcommittee that has
jurisdiction over NIH spending, is leaving, too, creating
a zone of uncertainty.
Whether biomedical research is undergoing a crisis
or is evolving to respond to changes in the health care
environment is a key question. Attempts to answer it are
likely to consume the field and the policy community for
some time to come. To focus the debate, NHPF is
launching an examination of the concerns confronting
biomedical research, as well as the conflicting priorities
and the operational realities that are crucial to its suc-
cess. Centering on the policy implications—especially in
the interaction of the federal and private sectors and
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their impact on the public’s health—the Forum will
conduct a series on the purpose, process, financing, and
benefit of different aspects of biomedical research in
this country.
THE FEDERAL COMPONENTS
The biomedical research complex is generally con-
sidered to be nearly a half-century old, especially if
viewed through the lens of the NIH. The NIH actually
traces its history to the authorization of a Marine
Hospital Service in 1798; the establishment of a Hy-
giene Laboratory at Marine Hospital, Staten Island, in
1887; and the renaming of the Hygiene Laboratory as
the NIH in 1930. However, the NIH was an insignifi-
cant player in biomedical research until Congress
started directing funds to it in the post-World War II
years. During the 1950s, the NIH grew rapidly as it
became a key part of a research complex supported by
the federal government and the pharmaceutical indus-
try. The postwar advancement of AHCs as medical
service, education, and research entities spurred this
growth.1
Today, the NIH includes the Warren Grant
Magnuson Clinical Center, an intramural research
facility at its campus in Bethesda, Maryland, that has
half the designated research beds in the country, and 75
General Clinical Research Centers, extramural research
facilities located at AHCs throughout the nation. NIH
also has the following institutes:
 National Cancer Institute (NCI),
 National Eye Institute,
 National Heart, Lung, and Blood Institute,
 National Human Genome Research Institute,
 National Institute on Aging,
 National Institute on Alcohol Abuse and Alcohol-
ism,
 National Institute of Allergy and Infectious Dis-
eases,
 National Institute of Arthritis and Musculoskeletal
and Skin Diseases,
 National Institute of Child Health and Human
Development,
 National Institute on Deafness and Other Communi-
cation Disorders,
 National Institute of Dental Research,
 National Institute of Diabetes and Digestive and
Kidney Diseases,
 National Institute on Drug Abuse,
 National Institute of Environmental Health Sciences,
 National Institute of General Medical Sciences,
 National Institute of Mental Health,
 National Institute of Neurological Disorders and
Stroke, and
 National Institute of Nursing Research.
The NIH also includes the following:
 National Library of Medicine,
 John E. Fogarty International Center for Advanced
Study in the Health Sciences,
 National Center for Research Resources,
 Center for Information Technology, and
 Center for Scientific Review.
As already indicated, other federal agencies are also
important components of the biomedical research
complex:
 The youngest is the Agency for Health Care Policy
and Research (AHCPR), which Congress is currently
in the process of renaming the Agency for Health
Research and Quality (AHRQ). Established in 1989,
it conducts health services research on access, cost,
and quality issues. Among other units, it has centers
to probe practice and technology assessment, primary
care, outcomes and effectiveness, and quality man-
agement and improvement.
 The Centers for Disease Control and Prevention
(CDC) date to 1946, when the CDC was called the
Communicable Diseases Center. The CDC received
its current name in 1970. The agency works on
disease and injury prevention and environmental
health. Among other components, it has centers
focused on chronic disease; HIV, socially transmitted
diseases, and tuberculosis; infectious diseases;
immunization; occupational safety and health;
genetics; and public health practice.
 The Food and Drug Administration (FDA) dates to
1927, when it was established as the Food, Drug, and
Insecticide Administration. It became the FDA in
1930. Responsible for food, cosmetic, drug, medical
device, and radiation-emitting product safety (as well
as medicines and drugs for pets and farm animals), it
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operates through a number of centers, some of
which focus on research. Examples are the Center
for Biologics Evaluation and Research, Center for
Drug Evaluation and Research, and National Center
for Toxicological Research.
 The Health Care Financing Administration (HCFA),
established in 1977 to bring the administration of
the Medicare and Medicaid programs under one
agency, has a research and demonstration arm that
investigates delivery of services for the two pro-
grams and for CHIP, created in 1997. Administra-
tive costs are less than 3 percent for the agency,
which has responsibility not only for administering
the two public health delivery and financing pro-
grams but also for implementing federal quality
assurance standards in clinical laboratories, nursing
homes, hospitals, home health agencies, ambulatory
surgical centers, hospices, and other facilities. For
example, as part of its responsibility for informing
coverage decisions, HCFA has become involved
with the NCI in supporting clinical trials for a study
on lung reduction surgery for chronic obstructive
pulmonary disease.
 The oldest agency is the VA. It achieved cabinet
standing in 1989 but goes back to 1917, when the
United States entered World War I. Three different
agencies administered veterans’ programs in the
1920s, until the Veterans Administration, precursor of
the VA, came into being in 1930. The VA has four
service areas that are involved in R&D. They include
the Medical Research Service, which works on
fundamental biological processes; the Cooperative
Studies Program, which handles clinical trials; the
Health Services Research and Development Service,
which looks at accessibility, effectiveness, efficiency,
and quality; and the Rehabilitation Research and
Development Service, which addresses disability and
functional concerns. The VA claims such develop-
ments as the cardiac pacemaker, the first kidney
transplant, a vaccine for hepatitis, and the magnetic
resonance image scan for diagnosis.2
The NIH, AHCPR (or AHRQ), CDC, FDA, and
HCFA are part of the Department of Health and Human
Services (DHHS). In addition to DHHS and VA, the
Departments of Agriculture, Defense, Education, and
Energy direct, or are involved to some extent in,
biomedical research initiatives, too.
While the NIH, aside from an occasional blip, has
enjoyed ongoing support, the other agencies have
experienced ups and downs. AHCPR, for example, was
almost eliminated in the mid-1990s. Just re-authorized
under legislation that extends its purview, it fared better
this year than HCFA, which experienced a cut in admin-
istrative funds in its FY 2000 appropriation. Researchers
and advocates alike are looking at funding allocation
decisions, raising questions about research and funding
priorities in the decade to come. While traditional
allocation debates have centered on basic versus clinical
research, translational and outcomes initiatives are
increasingly finding their way into discussions of
biomedical research funding priorities.
THE PRIVATE COMPONENTS
One of the most striking aspects of biomedical
research over the past two decades or so is the expansion
of the private sector. The funding balance has shifted
from the public to the private sector, resulting in a shift
in who calls the shots on decisions over what to fund
and how much to allocate.
Although the NIH budget has more than doubled in the
past 10 years, its share of total health R&D expendi-
tures in the United States has decreased from about 35
percent in the mid-1980s to about 29 percent today.
Over the same period, industry’s share of total health
R&D expenditures has increased from 34 percent to 43
percent.3
Rapid Growth in Pharmaceutical,
Biotechnical, and Medical Device R&D
The pharmaceutical industry invested an estimated
$20.6 billion in 1998, a 10.7 percent increase over the
estimated $18.6 billion it spent in 1997. While the figures
are hard to come by, the Pharmaceutical Research and
Manufacturers of America (PhRMA) reports that approxi-
mately 25 percent of R&D is devoted to research on
products acting on the central nervous system and sense
organs (which play a role in Alzheimer’s, schizophrenia,
depression, epilepsy, and Parkinson’s). PhRMA indicates
that 21 percent goes to products affecting neoplasms, the
endocrine system, and metabolic diseases (cancer, osteo-
porosis, and diabetes); 15 percent to cardiovascular
disease; 19.5 percent to parasitic and infectious disease;
and 5.6 percent to products for diseases of the respiratory
system (including asthma).4
Overall, nearly 33 percent of firm-funded R&D is for
evaluation of drugs in human clinical trials, 41 percent
for pre-clinical R&D functions, 11.8 percent for synthe-
sizing and extracting compounds for evaluation, 14.9
percent for biological screening and pharmacological
testing, 5.4 percent for later toxicology and safety
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testing, and 8.5 percent for dosage formulation and
stability testing.5
The smaller biotechnology companies—numbering
approximately 1,500, with only about 20 percent
having approved products and incoming revenues and
only 30 percent or so having “a stock market value
greater than $1 billion”—are in a different situation
than the large firms represented by PhRMA. “But the
industry is soon to turn a corner, its leaders say, be-
cause almost 300 biotech medicines are in late-stage
clinical trials,” Neil Munro reported in the National
Journal.6 The field of gene therapy seems to be experi-
encing its ups and downs, however. The Wall Street
Journal reported in October 1999 that gene-therapy
drugs are in a “delivery shortfall,” as biotech firms seek
to resolve various technical problems.7
Medical equipment manufacturers and suppliers
also have a large stake in biomedical research. Nearly
$70 billion in medical devices and diagnostic products
were produced in 1998, according to the Health Indus-
try Manufacturers Association. Most of the medical and
diagnostic equipment was consumed in the U.S.
market. Examples of products include electro-medical
devices and equipment, surgical and medical instru-
ments, diagnostic reagents, orthopedic devices and
surgical supplies, and dental equipment.8
Addressing the role that the industry plays in
biomedical research, Munro contended in his article
that biotechnology firms have an “enormous depend-
ency on governing funding, regulation, and protection.”
He said that “even the large, mostly cautious, pharma-
ceutical firms,” which in part are insulated by their
international sales, are “sometimes deterred from
investigating a controversial area” because a policy
change may crimp a controversial product. He under-
lines the links between the pharmaceutical industry and
“drug-safety laws intended to ensure that it cannot
market any product until government regulators give
permission, while modest profits make it dependent on
Wall Street investment capital, which tends to flee from
controversy.”9 The medical and diagnostic product
industry finds that its success, also, is closely linked to
government policies, as well as to its ability to raise
venture capital to develop new products.
Varying Responses from Managed Care
Plans, PBRNs, and CROs
MCOs’ participation in health research has been
mixed, with health plans such as Kaiser Permanente
involved and others reluctant to devote dollars to the
field. However, large MCOs seem to be naturals for the
conduct of research—especially clinical trials, health
outcomes initiatives, and health economics studies—
because of their pools of physicians and other practitio-
ners, use of ambulatory settings, links to AHCs, and access
to patients as potential research subjects. Referring to a
study of managed care plans’ impact upon clinical re-
search (for the most part, viewed through the lens of
AHCs’ conduct of research), Robert Mechanic and Allen
Dobson pointed out in a 1996 Health Affairs article:
Managed care plans’ clinical research priorities differ
from traditional AMC [academic medical center] activi-
ties. As plans become major players in specific markets,
there is a growing need for research partnerships. Many
of the managed care plans we interviewed already are
involved in a range of research activities, including
clinical trials, outcomes research, and health services
research, although their basic research and clinical trial
activities are smaller than those of AMCs. Managed care
plans are most interested in applied research that is
focused on measuring the cost-effectiveness of treat-
ments for conditions that are common among their
enrollees. In contrast, medical school faculty historically
have concentrated on basic research and clinical trials,
with substantial focus on rare diseases. Much of the
research conducted at AMCs is not perceived as address-
ing the immediate clinical needs of managed care plans
or as devoting adequate attention to economic reality.10
Speaking to the American Association of Health
Plans (AAHP) conference in 1997, NIH Director
Varmus cited studies in trade journals that accused
“market forces” as hindering scientific investigation.
While not directly accusing MCOs, he suggested several
ways in which managed care plans could step forward:
(a) to work with stakeholders from the research commu-
nity and health care purchasers to develop core princi-
ples, (b) to study cost differences between standard care
and research-related care, and (c) to develop pilot
projects that would encourage plan participants to take
part in clinical studies.11
One point of contention has been managed care
plans’ refusal to pay health care costs for their members
who are involved in clinical trials. Early in 1999, NIH
and the AAHP drew up an agreement under which
managed care plans would try to increase the number of
their patients in NIH-approved and -financed clinical
trials. For example, United Healthcare Corporation,
acknowledging that only 2 percent of eligible cancer
patients are involved nationwide in clinical trials,
indicated that the firm would begin by covering the costs
of its cancer patients who took part.12
While some MCOs may hang back when it comes to
clinical trials, other organizations have been eager to move
forward. An estimated 35,000 industry- and government-
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sponsored trials currently are going on. The demand for
trial participants—and the need for mechanisms to
organize the various phases of clinical trials and testing of
new drug therapies in humans—has given rise to new
modalities. The Internet—providing easy access to
patients and physicians who are seeking information
about investigational treatments—has spurred a network
of pharmaceutical companies, research organizations, and
provider groups that sponsor clinical trials and design
research protocols. For example, a person seeking
information may go to www.CenterWatch.com to find
trial listings, new FDA drug approvals, and other leads.
PBRNs, “networks of physicians who have agreed
to implement research protocols and data collection in
studies ranging from pediatric physiology to outcomes
assessment,” have been developing since the early
1980s. “There were more than 27 such networks active
in 1994, involving more than 6,000 participating clini-
cians,” according to a 1999 AAMC paper, “The
Changing Landscape for Clinical Research.”13 They are
involved in the conduct of clinical research, outcomes
research, and development of clinical guidelines.
Examples include the Ambulatory Sentinel Practice
Network (affiliated with the American Academy of
Family Practice), the Dartmouth Cooperative Project in
New England, and the Pediatric Research in Office
Settings network (established by the American Acad-
emy of Pediatrics), according to the paper.
New entrants to biomedical research in the 1990s
were CROs, organizations devoted to performing
clinical trials more quickly and more cheaply than
AHCs. Examples of CROs include Covance, Parexel,
and Quintiles, all of which offer “integrated product
development,” ranging from study design to monitoring
and management. Organized to outsource clinical
services and to establish multiple sites, CROs exist and
operate outside AHCs. They may compete directly with
AHCs or they may collaborate with them, but their
growth generally seems to have contributed to declin-
ing participation in trials by AHCs.
A September 1999 report by the General Accounting
Office, NIH Clinical Trials: Various Factors Affect
Patient Participation, indicated that “patients may enter
into trials in a range of settings, including community
hospitals and physician offices,” but credited the
pharmaceutical industry with supporting “the majority
of large clinical trials that determine therapeutic effi-
cacy of new drug products.” It said that an official of
PhRMA “estimated that drug trials represent about 75
to 80 percent of all approved trials in the United States
and that pharmaceutical companies sponsor about 80
percent” of them. The report also stated that PhRMA
“estimated that trials of medical devices represent less
than 5 percent of all approved trials and that nondrug
therapies, such as new surgical or radiation treatments,
represent about 10 percent.” The rise of specialty organi-
zations to organize these trials is a phenomenon that
seems to receive much less attention in policy circles
than the roles of the NIH, AHCs, and even MCOs.
THE PRESSURES UPON AHCS
Beginning after World War II, AHCs became the
linchpins for biomedical research. NIH funded research
projects through clinical investigators at AHCs.
AHCs—buoyed by Medicare dollars from the mid-
1960s on—took on tripartite missions that joined service
delivery, medical education, and research. Teaching
hospitals at AHCs became the disseminators of new
procedures, drugs, devices, and even evaluative tech-
niques. As the biomedical research enterprise grew,
AHCs—whether operated by public or by private
academic institutions—flourished.
“But for all of its appearance of robustness and
prosperity, the enterprise remained dangerously under-
capitalized and highly leveraged on public support of
research and on patient care funds,” contended the
AAMC paper. “In sum, clinical research in academic
medical centers became extraordinarily susceptible to
modifications of federal policies of sponsored research
support and changes in the organization, financing, and
delivery of medical care.”14
As the health care marketplace reconfigured, it
placed greater value on delivery of services in ambula-
tory settings and on financing of care through capitated
or otherwise discounted arrangements. AHCs, heavily
dependent upon acute, inpatient settings and upon
commingled patient service, medical education, and
research dollars, tended be less flexible than other
providers in responding to the new marketplace incen-
tives. While AHCs had pioneered various medical and
management techniques, they tended to overutilize acute
and specialty services and to experience excessive costs,
both of which turned out to be the Achilles heels of
AHCs, according to Gordon T. Moore, M.D., of Har-
vard Pilgrim Health Care.15 Another vulnerability was
patient flow, as health plans provided many services—
even surgical care—in nonhospital settings and diverted
acute care to less expensive providers, such as commu-
nity hospitals.
The Medicare Payment Advisory Commission
(MedPAC) took on the higher cost issue directly in
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1999, when it examined Medicare’s graduate medical
education (GME) payment policies:
The higher patient care costs observed in teaching
hospitals reflect a number of factors that are likely to
strengthen the clinical care Medicare beneficiaries and
other patients receive. Compared with other hospitals,
teaching facilities tend to undertake more applied
clinical research aimed at developing and testing new
diagnostic and therapeutic technologies, such as imag-
ing methods, drugs and devices, and surgical proce-
dures. They also tend to hire a more costly mix of staff,
including teaching faculty and technical specialists
needed to provide advanced training, research, and
patient care. Consequently, teaching facilities generally
offer a broader and more technically sophisticated array
of services, attract patients who are more acutely ill, and
furnish care that is more complex and costly, than do
other hospitals.16
As care has become increasingly managed—by
private insurers, in state Medicaid plans, and even
through Medicare+Choice—AHCs have had fewer
opportunities to cross-subsidize and commingle funds.
Moreover, as medical economics has changed, the
incentives for practitioners to take part in research have
altered as well, particularly resulting in a decline in the
number of physicians interested in or involved in
clinical investigation. All of these shifts have led
AHCs—and those who represent them—to point to a
crisis in biomedical research and to the clinical investi-
gator as an endangered species.
These changes have also threatened the traditional
partnerships (with NIH, with pharmaceutical and medical
device companies, and with various providers) under
which AHCs have operated. As indicated by David
Blumenthal, M.D., in a 1994 Health Affairs article, a
series of legislative statutes enacted during the 1980s
encouraged links between private firms and academic
researchers. For a variety of reasons—including new
types of research, investment decisions, and proprietary
rights—the nature of the relationships appears to be
changing and the shape they will take in the future is not
at all clear.
RISING TENSIONS AS THE FIELD
RECONFIGURES
As the field of biomedical research has evolved in
response to a rapidly changing health marketplace and
to shifting economic incentives in the field itself,
various tensions have arisen or deepened. These in turn
are causing policymakers and others in the health arena
to look at the pressures on the research enterprise, the
nature of the U.S. system, the process of setting research
priorities, the cost implications, and the impact upon the
public health. The following are some of these tensions:
 Competition among advocates of biomedical re-
search directed toward specific diseases. Jockeying
among disease lobbies has concerned observers of
the field since biomedical research became a signifi-
cant part of the federal budget. However, until
recently, the concern was fairly minor because
disease groups tended to avoid open warfare and,
when it was crucial, work together to get as much
funding for biomedical research as they could.
By the mid-1990s, however, a new trend had
emerged. Although some interest groups still
pursued general increases, . . . certain disease-
specific interest groups adopted a narrower ap-
proach. Citing the success of HIV/AIDS and breast
cancer lobbyists in obtaining high levels of tar-
geted research funds, groups representing persons
with Parkinson’s disease, prostate cancer, diabetes,
and other conditions explicitly requested congres-
sional mandated (“earmarked”) funds to support
their areas of interest.17
Certainly, the success of the AIDS and breast cancer
lobbies set a standard for other disease groups to
strive for. AIDS and breast cancer advocates upped
the ante as they organized grass-roots support, gained
congressional champions and celebrity backers, and
sponsored special fund-raising events.
 Alignment of biomedical research priorities in a
pluralistic system. While countries such as France,
Germany, and Japan have government-directed
biomedical research, the United States has a decen-
tralized system. While the NIH serves as an empow-
ering agency (as do, to a certain extent, some of the
other agencies of government that are involved in the
research enterprise), it does not have the power to set
overall priorities. Instead, priorities sort themselves
out in the marketplace, largely driven by economic
incentives. Some believe that this is the strength of
the U.S. biomedical research enterprise, while
others—worried about the growing dominance of the
for-profit sector—contend it results in misalignment
of priorities and outcomes. Because of government’s
strong role as a regulator, however, protection of “the
public good”—such as in establishing incentives or
subsidies for the development of “orphan drugs” for
obscure conditions—is its responsibility.
 Allocation of biomedical research dollars and efforts
between basic and clinical research, as well as among
different areas of DHHS. The conflict over spending
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for basic versus clinical research is a constant con-
cern. “The clinical research communities have been
less successful than the basic science disciplines in
articulating their needs for a nurturing physical and
intellectual environment within the context of scien-
tific opportunities and the health care needs of the
public,” the AAMC article contended.18
At the same time, there are those who criticize the
emphasis upon basic and clinical research, at the
expense of health services, preventive and environ-
mental, quality assurance, and disability-oriented
research. Commenting on the current campaign to
double the NIH budget, CQ Weekly reporter Sue
Kirchhoff wrote: “The campaign has intensified a
longtime contest for money between NIH and other
programs in the Labor/DHHS spending bill, such as
Head Start and jobs programs.” She quoted Rep.
Nancy Pelosi (D-Calif.) as calling the fight over the
funding items in the appropriations bill a “lamb eat
lamb” battle. Rep. David Obey (D-Wis.), ranking
minority member of the Labor/DHHS appropria-
tions subcommittee, has been one of the major
critics of increasing NIH funding at the expense of
other social programs.19
 Charges of conflicts of interest among researchers
and institutions, suppressed discoveries, and chal-
lenged intellectual property rights. As private
industry support of university biomedical research
rose from less than 4 percent in the 1950s and 1960s
to 14 percent in 1997, concern grew over possible
conflicts of interest on the part of industry-backed
university researchers. According to David Blumen-
thal, the “distance” between biomedical researchers
and industrial organizations decreased during the
1970s and 1980s as a result of several factors. These
include the close ties between academic researchers
and the biotechnology firms that sprang up during
the period, trade and budget deficits in the U.S.
economy during the Carter and Reagan administra-
tions, and federal encouragement of public-private
partnerships in the Reagan era.20
Various charges have circulated about suppression
of research results that might cause “dislocations” in
the biomedical research field. Columnist Daniel S.
Greenberg has written a steady flow of columns
attacking the biomedical research enterprise—and
entrepreneurs. In 1998, he contended:
A case in point is the discovery 20 years ago of an
amino acid in the blood, homocysteine, that is
now considered to be a major source of heart
disease, perhaps on a par with cholesterol. But, as
described in the New York Times Magazine last
year, the discoverer, Dr. Kilmer McCully, was
consigned to scientific oblivion because his find-
ings conflicted with NIH’s reigning dogma of
cholesterol as the culprit in heart disease.21
Earlier—in 1997—the New England Journal of
Medicine reported that research on spinal fusion
surgery, multiple chemical sensitivity, and calcium
channel blockers for the treatment of blood pressure
had been suppressed. The implication is that research-
ers must “go along to get along.” At the same time, as
delineated in depth by Blumenthal, there is the implica-
tion that researchers have strategic alliances, patenting
and licensing arrangements, and even partnerships
(say, in the creation of new biotech companies) with
industry.22 At times, there have been conflicts over
intellectual property rights regarding research, particu-
larly when research findings’ translation and applica-
tion have resulted in lucrative products.
 Politicization of biomedical research (especially in
the congressional setting), as exemplified by the
fetal-tissue and stem-cell research issues. Related to
the polarization of the Congress over the “right to
life” versus “choice” abortion issue, some research
topics have become embroiled in politics, resulting in
congressionally mandated bans against or funding
restrictions on certain types of research. The most
prominent example is fetal tissue research. In fact,
NIH has lacked an actual authorization since 1996
because of that issue (although funds have been
appropriated).23 Stem-cell research is just as contro-
versial. “Opponents decry the research as lethal
human experimentation, but supporters say it will
create marvelous new medical treatments for myriad
diseases and ailments.”24
 Rising costs of health care said to be direct results of
advances in biomedical research. According to Peter
J. Neumann and Eileen A. Sandberg, writing in
Health Affairs:
Spending on health R&D, which reached $35.8
billion in FY 1995, increased as a percentage of
total health expenditures from 3.2 percent in FY
1986 to 3.5 percent in FY 1995. During the same
period, health R&D spending as a fraction of total
R&D spending rose from 12.5 percent to 20.3
percent.25
Critics, however, point to cost trade-offs such as the
prevention of costly illnesses and disabilities as a
result of new modalities and the substitution of less
expensive drugs or procedures for more costly ones
as a result of new developments. And, of course, they
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cite improvements in the quality of patients’ lives as
well as in the number of lives saved.
 Questioning of the public interest in biomedical
research and the benefits to different segments of
the population. While researchers tout improving
the health of the public as the overriding rationale
for biomedical research, some observers question
whether various segments of the public are benefit-
ting. Three researchers, associated with the Robert
Wood Johnson Clinical Scholars Program, looked
at NIH funding relative to the burden of disease.
They found that AIDS, breast cancer, diabetes, and
dementia tended to receive relatively generous
funding, whatever the measure (incidence, preva-
lence, or number of hospital days). They indicated
that chronic obstructive pulmonary disease, peri-
natal conditions, and peptic ulcer research was
relatively underfunded.26 NIH has also conducted
studies on the burden of disease. Critics are quick to
lash out, saying that one disease is bleeding funding
from another. For instance, when AIDS entered the
scene in the 1980s, its success in drawing research
monies caused resentment in some quarters and
there is currently much debate over the dispropor-
tionately low funding for research on breast cancer
relative to prostate cancer.
When it comes to segments of the population, various
observers have raised concerns about the incidence
and mortality of certain diseases among members of
various minority groups, as well as about the partici-
pation of minorities and women in various aspects of
the biomedical research enterprise. For example, an
IOM panel indicated that African-American males
“develop cancer 15 percent more frequently than
white males” and that African-American women are
less likely to have breast cancer than white women but
are more likely to die from it once it is detected. They
said that, compared to the national average, Asian-
Americans have higher rates of stomach and liver
cancers, Alaska Natives are at higher risk for colon
and rectal cancer, and Hispanic and Vietnamese-
American women have a greater likelihood of getting
cervical cancer.27 As the costs of drugs continue to
rise, advocates for the uninsured and underinsured
express concerns that they may be denied access to
life-saving and life-enhancing treatments solely on the
basis of cost.
Among the panel’s conclusions were these:
The committee believes that NCI and NIH should
improve the accuracy of their assessment of the
amount of resources allocated to addressing the
needs of ethnic minority and medically underserved
populations. . . . Research has so far failed to take
advantage of the diverse populations of the United
States in understanding the causes of cancer and
reducing mortality. . . . There is little evidence that
NCI or NIH has undertaken a thorough assessment
of training programs to determine whether these
programs are producing adequate numbers of ethnic
minority researchers in all appropriate cancer re-
search fields. . . . Ethnic minority participation in
NCI-supported clinical treatment trials appears to be
proportional to the incidence of cancer among these
groups, but it is lower than expected in cancer
prevention trials.28
PROPOSALS FOR SETTING AND
IMPLEMENTING PRIORITIES
Various groups that convened during the 1990s have
numerous recommendations on the form that biomedical
research should take. While these recommendations tend
to concentrate on clinical research—where most see the
bulk of the problems—they include other aspects of
biomedical research as well. Although the Forum will
look at other proposals too, it will focus on four major
initiatives. These include an NIH director’s panel study
of priority-setting at the NIH, an IOM study of priority
setting at the NIH, an examination of AHCs’ research
mission by the Commonwealth Fund, and an AAMC-
AMA-Wake Forest School of Medicine clinical research
summit.
The NIH Director’s Panel on Clinical
Research
The NIH director’s panel, chaired by David G.
Nathan, M.D., met from 1995 to 1997. Focusing primar-
ily on policy changes that would encourage physician
investigators to undertake careers in clinical research, it
urged the following:
 Reinforcement of the NIH’s commitment to basic
and clinical research (underlining the latter).
 Strengthening of the General Clinical Research
Centers’ infrastructure in individual AHCs and
monitoring of the productivity of the Warren
Magnuson Clinical Center.
 Extension of the Howard Hughes Medical Institute
medical student program from basic science to
clinical research.
 Upgrading of training programs and grants.
 Organization and restructuring of study sections that
review patient-oriented research applications.
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 Encouragement of collaboration between basic
scientists and clinical investigators.
 Both in basic science and clinical research, support of
collaboration between pharmaceutical and biotech-
nical companies and training programs in AHCs.
 Initiation of debt abatement for extramural clinical
investigators.
 Greater commitment by certain AHCs, such as
increased support to clinical research, extension of
data managers and auditors to the best clinical
investigators, hiring of additional clinicians, and
provision of efficient information systems.
 If it is determined that health insurance should
support selected clinical trials, participation by all
insurance providers.
 Collaboration by health insurers, foundations,
pharmaceutical and biotechnical companies, AHCs,
and the NIH in developing a joint policy for the
support of clinical research and clinical research
training.29
The IOM Committee’s Examination of
Opportunities and Needs
The IOM, in 1998, released the results of a study by
its Committee on the NIH Research Priority-Setting
Process. Headed by Leon E. Rosenberg, M.D., the
committee subtitled its report Scientific Opportunities
and Public Needs: Improving Priority Setting and
Public Input at the National Institutes of Health. The
report included recommendations on the following:
 Setting of criteria for priority setting.
 Recommendation of internal and external processes
to guide priority setting.
 Suggestion of new mechanisms to increase public
participation in the external process.
 Putting forth of ideas for clarifying the congressio-
nal role relative to priority setting.30
The Commonwealth Fund Task Force on
Academic Health Centers
Established in 1995 under the direction of Blumenthal
and Samuel Thier, M.D., the task force is scheduled to
work through 2001 on AHC missions. In April 1999, it
issued From Bench to Bedside: Preserving the Research
Mission of Academic Health Centers. The report contains
various findings, such as the following: “The United
States spends an estimated $42 billion annually on health-
related research and development” and AHCs “perform
approximately 28 percent of all health-related R&D in the
United States.” It makes one general recommendation: an
overall increase in federal support for health services
research.
The report contains the following suggestions
relative to AHCs:
 Better management of their research enterprise.
 Greater recognition of academic standing and pres-
tige of clinical and health services researchers.
 More investment in cross-disciplinary research
programs.
 Increased participation in applied research and
development.
 Enhanced positioning relative to managed care.
The report also recommends the following NIH
policies and expenditures regarding:
 More funding for construction and renovation of
research facilities.
 Increases in percentage of funds provided for pro-
jects and for investigators’ salaries.
 Maintenance of current levels of support for indirect
cost rates.
 Increase in support for clinical research at AHCs.
 Greater support for training of clinical researchers at
AHCs.31
The AAMC–AMA–Wake Forest School of
Medicine Clinical Research Summit
The AAMC, the AMA, and the Wake Forest Univer-
sity School of Medicine—with funding from the Bur-
roughs Wellcome Fund, the Robert Wood Johnson
Foundation, the Pew Charitable Trusts, the John D. and
Catherine T. MacArthur Foundation, the Merck Com-
pany Foundation, the Commonwealth Fund, and the
Wake Forest University Ethics and Leadership
Fund—undertook a major initiative in 1998. Drawing on
focus groups and leaders from diverse sectors of the
health community, they addressed what they viewed as
a crisis in clinical research: a declining number of
physician scientists, a decreasing pool of younger
researchers, a steady reduction in cross-subsidization of
research in AMCs, a gradual shift toward targeted
proprietary research, and a growing scarcity of patient
bases for the conduct of clinical studies. Seeing multiple
opportunities for clinical research, they underlined that
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clinical research is critical to the flow of scientific
discovery and developed recommendations to preserve
and enhance it.
Saying that clinical research encompasses a wide
range of functions, from disease mechanisms to health
services research, they outlined eight problems that it
faces:
 Need for an agreed-upon definition of “clinical
research.”
 Lack of adequate understanding and value.
 Absence of data to monitor and assess the different
components of clinical research.
 Inadequate numbers of appropriately trained clinical
investigators.
 Insufficient emphasis on incorporating research
findings into clinical practice.
 Inadequate coordination of clinical research within
and between research entities and disciplines.
 Restricted ability of AMCs to conduct clinical
research.
 Lack of a comprehensive, dynamic clinical research
agenda.
Those who participated in the three organizations’
consensus process concluded that there is a need for a
clinical research roundtable to continue and focus
national attention on the needs, priorities, and progress
of clinical research and training. They urged that the
roundtable be established at the turn of the century so
that it can start undertaking its important work and
recommended that the IOM be its headquarters. After-
ward, the IOM agreed to establish a clinical research
roundtable to build on the work of the summit.
The clinical research roundtable would have the
following goals:
 To promote dialogue among the scientific commu-
nity and the general public to create mutual under-
standing about clinical research and the public’s
participation in it.
 To strengthen the ethical underpinnings of clinical
research.
 To establish mechanisms to track and disseminate
the aggregate levels of financial and other support
for each of the major categories of clinical research.
 To create a process to monitor and promote
workforce career development across the health
professions to meet the needs and promote the
different categories of clinical research.
 To develop databases for patient- and population-
based health research.
 To strengthen the linkages between basic science
discoveries and their application to improved patient
care.
 To ensure AHCs’ ability to conduct research and
training.
 To broaden the participation of the health professions
in clinical research across all practice settings.
 To develop and monitor strategies involving the
dissemination of new clinical research findings and
the evaluation of the outcomes of new procedures
and treatments.32
Backing and Leadership
As reflected in the sponsorship of some of the panels,
private foundations play a strong role in the biomedical
research arena. “Philanthropic organizations historically
were responsible for stimulating and enabling the incul-
cation of science into medical teaching and practice, and
the transformation of the nation’s premier medical
centers,” the AAMC paper stated. “These organizations
contributed $1.3 billion to biomedical and health-related
research in 1997, an increase of nearly 30 percent from
$942 million in 1995.”33 Whether in providing grants
directly for biomedical research, underwriting new
facilities, supporting clinical fellowship programs, giving
grants for clinical or policy conferences, or engaging in
other initiatives, foundations have provided leadership to
the biomedical research field.
Various interest groups, whether associated with
specific diseases or banded into coalitions to support all or
certain aspects of biomedical research, have contributed
significantly as well. Examples include disease groups
such as the American Arthritis Foundation, the American
Cancer Society, and the American Diabetes Association.
Coalitions include the Ad Hoc Group for Medical Re-
search Funding (medical and scientific societies, voluntary
health organizations, and academic and research institu-
tions), Campaign for Medical Research (also various
groups), the Friends of VA Medical Care and Health
Research (various organizations interested in veterans’
health care), the National Health Council (a band of
voluntary and corporate organizations), NIHX2 (a group
of pharmaceutical companies), and Research! America (a
large alliance of providers, researchers, professional and
trade associations, corporate organizations, and others).
 12 
1. See Karen Matherlee, The Outlook for Clinical Research:
The Impacts of Federal Funding Restraint and Private Sector
Reconfiguration, National Health Policy Forum Issue Brief
No. 671, July 6, 1995, 3.
2. Department of Veterans Affairs, “Highlights of VA
Research and Development Accomplishments;” accessed at
http://www.va.gov/resdev/highlights.htm, October 10, 1999.
3. Pharmaceutical Research and Manufacturers of America
(PhRMA), “Collaboration between the National Institutes of
Health and Industry,” PhRMA Publications: Industry Profile
1998; accessed at http://www.phrma.org/publications/indus-
try/profile99/chap2.html, October 9, 1999.
4. PhRMA, “Collaboration.”
5. PhRMA, “Collaboration.”
6. Neil Munro, “Frontier Ethics,” National Journal, June 5,
1999, 1519.
These highlight the search for leadership in biomed-
ical research, which is exacerbated by the departure of
Varmus and Porter. Various proposals, such as the NIH
director’s panel recommendations to strength NIH’s
role, the IOM’s call for greater public participation, the
Commonwealth Fund task force’s efforts to bolster
AHCs, and the AAMC-AMA-Wake Forest call for a
clinical research roundtable, reflect a quest for leader-
ship in focusing biomedical research’s missions and
achievements in the first part of the next century.
Some Key Questions
This Forum series will raise numerous public policy
questions about the direction and funding of biomedical
research in this country:
 Is biomedical research in crisis? What are its prob-
lems?
 How are biomedical research allocations made
relative to the continuum of basic, translational,
clinical, and outcomes research?
 What pressures come to bear on the funding of
various aspects of research for specific diseases?
 Once funding allocation decisions are made, in what
ways can they change or be changed?
 Is biomedical research mainly based on a medical
model? On a health care model?
 What is the public interest in biomedical research?
Who or what is the public?
 Is the NIH budget too small? Should it be doubled?
If so, why? If so, how?
 What is the impact of biomedical research spending
on health care expenditures?
 Are federal research activities too compartmental-
ized? Too diverse?
 Are government agencies too paternal in their
approach to regulation? Not paternal enough?
 What is AHCPR’s (or AHRQ’s) role in biomedical
research? The CDC’s? The FDA’s? HCFA’s? The
VA’s? What should their roles be?
 Relative to AHCs, if they are to remain prominent
in clinical research, how should the necessary
infrastructure (for example, technology, information
systems, support for faculty) be funded? How do
they remain vital relative to changing health market-
place issues? How do they chart—or what part do
they play in—the education of the next generation
of clinical researchers?
 Should AHCs retain a strong role in biomedical
research? Should only some AHCs play a strong role?
Should the AHCs’ role be divided up among different
health care settings, both public and private?
 Should some AHCs cultivate clinical investigator
“stars” to conduct research?
 How have public-private partnerships advanced
biomedical research to date?
 Are intermediary organizations (for example, CROs)
contributing to advancement of biomedical research?
 Are biomedical research needs being met? What is
the outlook for the future?
 What impact do proprietary interests have on the
conduct and financing of biomedical research? On
the sharing of information? On intellectual property
rights?
 Should managed care play a greater role in biomedi-
cal research? What should its financial contribution
be? How should it contribute (for example, to an all-
payer fund, by funding health costs of its members in
clinical trials)?
 Is the research agenda clear?
 Should there be acknowledged leadership of biomed-
ical research or pluralistic leadership? Who decides?
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